Using genomic technologies and mouse modeling including patient-derived xenografts (PDX) and genetically engineered mouse models (GEMM), we are discovering and validating novel biomarkers and therapeutic targets of pediatric cancers
Settings
Save and close
Using genomic technologies and mouse modeling including patient-derived xenografts (PDX) and genetically engineered mouse models (GEMM), we are discovering and validating novel biomarkers and therapeutic targets of pediatric cancers
The overarching theme of the research in our group is to develop personalized medicine approach in pediatric oncology. We make use of the powerful combination of genomic technologies together with mouse modeling to understand the genetic changes underlying various types of pediatric cancers. Based on the knowledge of these genetic changes, we identify and validate biomarkers that could be used clinically to predict response to therapy and outcome. In addition, some of these genetic changes are also tested for potential therapeutic targets and when validated will ultimately lead to clinical trials. To accomplish all these goals, we have to develop effective international multi-institutional consortia to carry out team-based science that could translate laboratory research to clinical practice.